Last reviewed · How we verify
Pf-06804103 (pf-06804103)
PF-06804103 is a marketed drug by Pfizer Inc. for Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations. It has generated $21.2B in revenue. The mechanism of PF-06804103 is not specified on Wikipedia. PF-06804103 is a notable treatment option for patients with EGFR Exon 20 Insertion Mutations. Its clinical differentiation and commercial significance are significant in the pharma industry. There are limited pipeline developments for PF-06804103.
At a glance
| Generic name | pf-06804103 |
|---|---|
| Sponsor | Pfizer |
| Drug class | not specified |
| Target | EGFR Exon 20 Insertion Mutations |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- CYP2C8 inhibitors
- CYP2C8 inducers
- CYP2C9 inhibitors
- CYP2C9 inducers
- CYP2D6 inhibitors
- CYP2D6 inducers
- CYP3A4 substrates
Key clinical trials
- PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pf-06804103 CI brief — competitive landscape report
- Pf-06804103 updates RSS · CI watch RSS
- Pfizer portfolio CI